Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 130

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 130
---
opharma, Inc.

$1,708 lent to the Company by David Koos, the
Company’s sole Board Member and Officer, is due and payable at the demand of the holder and bears simple interest at a rate of 15%
per annum.

$15,000 lent to the Company by Zander Therapeutics,
Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics,
Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

$10,000 lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 4, 2025 and bears simple interest at a rate of 10% per annum.

$4,700 lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 15 2025 and bears simple interest at a rate of 10% per annum.

$4,500 lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 23 2025 and bears simple interest at a rate of 10% per annum.

Zander Therapeutics, Inc. and the Company are under
common control.

During the quarter ended December 31, 2024 BST Partners
lent the Company $46,599

BST Partners and the Company are under common control.

| 103 |

<div align='center'>Report of Independent Registered Public Accounting Firm</div>

To the Board of Directors

and Stockholders of Regen Biopharma, Inc. and Subsidiary

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Regen Biopharma, Inc. and Subsidiary (the “Company”) as of September 30, 2024 and 2023, the related statement of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt